Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
- Status
- UNKNOWN
- Phase
- PHASE1
Clinical Trials Related to Myelofibrosis
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
SARS-CoV-2 Donor-Recipient Immunity Transfer
- Status
- COMPLETED
- Phase
- N/A
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- Status
- RECRUITING
- Phase
- PHASE2
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
- Status
- TERMINATED
- Phase
- PHASE2
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
- Status
- COMPLETED
- Phase
- PHASE2
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
- Status
- COMPLETED
- Phase
- NA
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE3
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
- Status
- TERMINATED
- Phase
- PHASE3
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
- Status
- TERMINATED
- Phase
- PHASE3
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
- Status
- TERMINATED
- Phase
- PHASE2
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2